IL1B and atherosclerosis: One such approach involves targeting interleukin-1β (IL-1β) by monoclonal antibodies, such as Canakinumab, which may reduce cardiovascular events in patients with a history of AMI.[161] Indeed, emerging evidence suggests that low-dose colchicine may have benefits for patients with atherosclerosis by reducing the risk of recurrent cardiovascular events.